Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Are polynucleotides a safe alternative to HRT?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Polynucleotides are hormone-free and may be discussed when someone wants a non-hormonal option for vulvovaginal tissue quality, dryness or GSM-related discomfort. They are not the same as HRT and should not be presented as a proven replacement for vaginal ooestrogen or menopause care. Suitability depends on diagnosis, symptom severity, cancer or clotting history, fish allergy, infection screening and realistic expectations. A consultation should compare options rather than treating “non-hormonal” as automatically safer.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Composition
Highly purified trout DNA fragments with a high degree of spectral compatibility with human DNA.
Mechanism
Non-hormonal tissue regeneration, reactivating collagen and elastin deposition.
Safety
Biocompatible and protein-free, minimizing the risk of allergic or immunogenic responses.
Target Symptoms
Vaginal dryness, persistent itchiness, dyspareunia (painful sex), and loss of tissue elasticity.
Important safety note
Safety Profile: Polynucleotides undergo rigorous purification and sterilization (meeting CE safety standards) that removes all protein molecules, meaning there is low but not absent risk of an allergic reaction.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
How PN differs from HRT
Polynucleotides are not hormones; they are biostimulatory DNA fragments used for local tissue-quality support.
Alternative does not mean replacement
The page should compare PN with moisturisers, lubricants, local vaginal ooestrogen and menopause care rather than declaring one route best.
Evidence
Symptoms
Alternatives
What it means
Protocol Synergy: Polynucleotide therapy is often paired sequentially with hyaluronic acid (HA) to support extracellular matrix hydration and consolidate tissue benefits.
Why symptoms matter
Cellular Action: Unlike simple lubricants, polynucleotides act at a cellular level by regulating water balance, triggering fibroblast repair, and creating new micro-blood vessels (angiogenesis).
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Delivery Route: Administered via intradermal or mucosal infiltrations (injections) directly into the labia majora or affected vulvovaginal tissues.
What this means in practice
Delivery Route: Administered via intradermal or mucosal infiltrations (injections) directly into the labia majora or affected vulvovaginal tissues.
Clinical Evaluation: Results are typically tracked over a 90-day protocol with assessments at days 21, 35, 50, 70, and 90.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Protocol Synergy: Polynucleotide therapy is often paired sequentially with hyaluronic acid (HA) to support extracellular matrix hydration and consolidate tissue benefits.
It protects safety
Safety Profile: Polynucleotides undergo rigorous purification and sterilization (meeting CE safety standards) that removes all protein molecules, meaning there is low but not absent.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Consultation: Begins with a thorough medical history assessment to evaluate GSM symptoms, check for contraindications, and set realistic expectations.
During care
Preparation: Patients must avoid blood-thinning supplements and report any acute illnesses or vaginal infections before their appointment.
Aftercare
The Procedure: Application of numbing cream followed by targeted polynucleotide injections.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Clinical Evaluation: Results are typically tracked over a 90-day protocol with assessments at days 21, 35, 50, 70, and 90.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: PN is HRT without hormones
Reality: polynucleotides are not hormones and work through local tissue-support mechanisms.
Myth: hormone-free is always safer
Reality: allergy, infection, bleeding and diagnosis still matter.
Myth: PN should replace vaginal ooestrogen
Reality: the best option depends on symptoms, risk profile and patient preference.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
NICE menopause recommendations
NICE supports assessment-led discussion of GSM, non-hormonal care and vaginal ooestrogen, including cancer-history nuance.
NHS information on vaginal ooestrogen
NHS patient guidance helps distinguish local vaginal ooestrogen from broader HRT discussions.
ACOG guidance on urogenital symptoms after ooestrogen-dependent breast cancer
This guidance supports shared decision-making and careful framing for cancer survivors with GSM symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 45 imported records. Additional reviewed material included clinical papers, guidance documents and patient-facing medical resources; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
